Action A226950 OLIX PHARMACEUTICALS, INC
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues OliX Pharmaceuticals, Inc

Actions

A226950

KR7226950004

Cours en clôture Korea S.E.
Autres places de cotation
 00:00:00 30/04/2024 		Varia. 5j. Varia. 1 janv.
15 670 KRW +1,10% Graphique intraday de OliX Pharmaceuticals, Inc +2,82% +7,48%
2023 OliX Pharmaceuticals, Inc. reçoit l'approbation du HREC pour lancer l'essai clinique de phase 1 d'un médicament contre la NASH et l'obésité CI
2023 OliX Pharmaceuticals annonce des données de sécurité positives et des effets d'efficacité préliminaires dans un essai de phase 1 d'OLX10212 pour le traitement de la dégénérescence maculaire liée à l'âge CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
OliX Pharmaceuticals, Inc announced that it has received KRW 14.7 billion in funding from a group of investors
OliX Pharmaceuticals, Inc announced that it expects to receive KRW 14.7 billion in funding from a group of investors
OliX Pharmaceuticals, Inc Receives HREC Approval to Initiate Phase 1 Clinical Trial of NASH and Obesity Drug
OliX Pharmaceuticals, Inc announced that it has received KRW 23.6 billion in funding from Kiwoom Investment Co., Ltd., AJU IB INVESTMENT Co., Ltd.
OliX Pharmaceuticals, Inc announced that it expects to receive KRW 23.6 billion in funding from Kiwoom Investment Co., Ltd., AJU IB INVESTMENT Co., Ltd.
OliX Pharmaceuticals Announces Positive Safety Data and Preliminary Efficacy Effects in a Phase 1 Trial of OLX10212 for Age-Related Macular Degeneration
OliX Pharmaceuticals, Inc. Announces First Patient in Phase 1 Clinical Study of RNAi Therapeutic OLX72021 for Androgenic Alopecia
OliX Pharmaceuticals, Inc Reports Earnings Results for the First Quarter Ended March 31, 2023
OliX Pharmaceuticals, Inc. Presents Preclinical Data Showing Synergistic Weight Loss from Anti-NASH siRNA and Semaglutide Combination Treatment
OliX Pharmaceuticals, Inc Inks MOU with DynamiCure Biotechnology to Develop ADC Immunotherapy Using RNA At Korea-US Digital BioHealth Business Forum
OliX Pharmaceuticals, Inc Announces Positive Results from A Phase 2A Trial of Olx10010 for Hypertrophic Scar Treatment
Olix Pharmaceuticals, Inc. Doses First Patient in Clinical Trial for Rnai Therapeutic Olx10212 for Dry and Wet Age-Related Macular Degeneration
OliX Pharmaceuticals, Inc. Receives Regulatory Approval to Commence Phase 1 Clinical Trial of Treatment of Androgenic Alopecia
PCL, Inc. terminated the acquisition of 40.76% stake in mCureX Therapeutics, Inc. from OliX Pharmaceuticals, Inc, Samyang Holdings Corporation, AJU Good Growth Support Fund managed by Aju IB Investment Co., Ltd. and Kiwoom New Hero Fund I managed by Kiwoom Investment Co., Ltd.
OliX Pharmaceuticals Publishes Preclinical Research Demonstrating OLX104C's Potential as an Effective Treatment for Hair Loss
Olix Pharmaceuticals Publishes Preclinical Research Demonstrating Olx104c’S Potential as an Effective Treatment for Hair Loss
OliX Pharmaceuticals, Inc agreed to acquire 6.63% stake in PCL, Inc. for KRW8.04 billion.
PCL, Inc. agreed to acquire unknown minority stake in stake in mCureX Therapeutics, Inc. from OliX Pharmaceuticals, Inc, Samyang Holdings Corporation, AJU Good Growth Support Fund managed by Aju IB Investment Co., Ltd. and Kiwoom New Hero Fund I managed by Kiwoom Investment Co., Ltd. for KRW12.2 billion.
OliX Pharmaceuticals, Inc Receives IND Approval from FDA to Develop RNAi Therapeutic OLX10212 for Age-Related Macular Degeneration
OliX Pharmaceuticals, Inc. Announces IND Submission to U.S. FDA to Evaluate Safety and Tolerability of OLX10212 in Phase 1 Clinical Trial
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action A226950
  4. Actualités OliX Pharmaceuticals, Inc
  5. Autres langues